JP7744746B2 - 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択 - Google Patents

真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択

Info

Publication number
JP7744746B2
JP7744746B2 JP2020530462A JP2020530462A JP7744746B2 JP 7744746 B2 JP7744746 B2 JP 7744746B2 JP 2020530462 A JP2020530462 A JP 2020530462A JP 2020530462 A JP2020530462 A JP 2020530462A JP 7744746 B2 JP7744746 B2 JP 7744746B2
Authority
JP
Japan
Prior art keywords
clones
binding agent
cells
binding
binder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020530462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021509010A (ja
JP2021509010A5 (enExample
Inventor
ジョン マカファーティ
ラジカ ペレラ
マイケル リチャード ダイソン
コタイ パルティバン
ジョアンナ リーナマリア シルジャネン
Original Assignee
イオンタス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イオンタス リミテッド filed Critical イオンタス リミテッド
Publication of JP2021509010A publication Critical patent/JP2021509010A/ja
Publication of JP2021509010A5 publication Critical patent/JP2021509010A5/ja
Priority to JP2023174103A priority Critical patent/JP2024009895A/ja
Application granted granted Critical
Publication of JP7744746B2 publication Critical patent/JP7744746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020530462A 2017-12-06 2018-12-05 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択 Active JP7744746B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174103A JP2024009895A (ja) 2017-12-06 2023-10-06 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1720351.4A GB201720351D0 (en) 2017-12-06 2017-12-06 Selecting for developability in drug discovery
GB1720351.4 2017-12-06
PCT/EP2018/083698 WO2019110691A1 (en) 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174103A Division JP2024009895A (ja) 2017-12-06 2023-10-06 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択

Publications (3)

Publication Number Publication Date
JP2021509010A JP2021509010A (ja) 2021-03-18
JP2021509010A5 JP2021509010A5 (enExample) 2022-01-06
JP7744746B2 true JP7744746B2 (ja) 2025-09-26

Family

ID=60950392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020530462A Active JP7744746B2 (ja) 2017-12-06 2018-12-05 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択
JP2023174103A Pending JP2024009895A (ja) 2017-12-06 2023-10-06 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174103A Pending JP2024009895A (ja) 2017-12-06 2023-10-06 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択

Country Status (8)

Country Link
US (1) US11499150B2 (enExample)
EP (1) EP3720959A1 (enExample)
JP (2) JP7744746B2 (enExample)
CN (1) CN111448314B (enExample)
AU (1) AU2018379426B2 (enExample)
CA (1) CA3083571A1 (enExample)
GB (1) GB201720351D0 (enExample)
WO (1) WO2019110691A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017205706B2 (en) * 2016-01-08 2022-10-20 Maxion Therapeutics Limited Binding members with altered diversity scaffold domains
GB201720162D0 (en) * 2017-12-04 2018-01-17 Univ Oxford Innovation Ltd Method
AU2020320910A1 (en) * 2019-07-30 2022-03-10 Akeso Biopharma, Inc. Anti-human p40 protein domain antibody and use thereof
GB202014851D0 (en) 2020-09-21 2020-11-04 Iontas Ltd SARS-COV-2 antibodies
CA3229003A1 (en) 2021-08-25 2023-03-02 Kothai Nachiar Devi PARTHIBAN Preparation of libraries of protein variants expressed in eukaryotic cells
WO2023039528A1 (en) * 2021-09-10 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nanobody-mediated control of gene expression and epigenetic memory
CN120677180A (zh) 2022-11-18 2025-09-19 赛斯米克治疗公司 Fc融合分子及其用途
US12129499B2 (en) 2023-01-06 2024-10-29 Seismic Therapeutic, Inc. Protease variants and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518362A (ja) 2014-05-02 2017-07-06 イオンタス リミテッド 真核細胞において発現されるタンパク質変異体のライブラリーの調製、及び結合性分子の選択に向けた使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
JP2010213725A (ja) * 1998-01-20 2010-09-30 Univ Illinois タンパク質の酵母細胞表面ディスプレイおよびその使用
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
SG194089A1 (en) 2011-04-27 2013-11-29 Amyris Inc Methods for genomic modification
BR112014013035A2 (pt) 2011-12-22 2018-10-09 Hoffmann La Roche métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518362A (ja) 2014-05-02 2017-07-06 イオンタス リミテッド 真核細胞において発現されるタンパク質変異体のライブラリーの調製、及び結合性分子の選択に向けた使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MABS, 2013, vol.6, no.2, pages 483-492, DOI:10.4161/mabs.27431
MABS,2016, vol.8, no.5, pages 941-950, DOI:10.1080/19420862.2016.1171444
SCIENTIFIC REPORTS, 2016, vol.6, no.1, pages 1-14, DOI:10.1038/srep38644

Also Published As

Publication number Publication date
CN111448314A (zh) 2020-07-24
AU2018379426B2 (en) 2025-05-22
GB201720351D0 (en) 2018-01-17
US20210163923A1 (en) 2021-06-03
JP2021509010A (ja) 2021-03-18
AU2018379426A1 (en) 2020-06-18
EP3720959A1 (en) 2020-10-14
WO2019110691A1 (en) 2019-06-13
CA3083571A1 (en) 2019-06-13
US11499150B2 (en) 2022-11-15
CN111448314B (zh) 2024-10-18
JP2024009895A (ja) 2024-01-23

Similar Documents

Publication Publication Date Title
JP7744746B2 (ja) 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択
AU2020202133B2 (en) Multi-specific monoclonal antibodies
JP5717833B2 (ja) 相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン
TWI875679B (zh) 藉由細胞表現之調控生物活性的抗體
Steven et al. In vitro maturation of a humanized shark VNAR domain to improve its biophysical properties to facilitate clinical development
US20190031770A1 (en) Intercalated single-chain variable fragments
EP4304725A1 (en) Rabbit-derived antigen binding protein nucleic acid libraries
JP2025524923A (ja) クローディン－６結合部分及びその使用
WO2023232110A1 (zh) 抗人cd24抗体及其应用
US20250066760A1 (en) Chimeric antigen receptor (car) vectors and libraries and methods of high throughput car screening
CN114075284B (zh) Cd47结合分子及其用途
WO2025152756A1 (zh) 重组抗fap抗体及其应用
JP2025533779A (ja) Ｇｃｃを標的とする抗体及びキメラ抗原受容体並びにそれらの使用方法
TW202525845A (zh) 基於ｃｔｌａ—４之溶體降解劑及其用途
Huhtinen ADVANCING ANTIBODY ENGINEERING
KR20220087488A (ko) Pd-l1 결합 분자
HK40013903A (en) Multi-specific monoclonal antibodies
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200720

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250912

R150 Certificate of patent or registration of utility model

Ref document number: 7744746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150